Arctoris To Overhaul Drug Discovery With Automation
Building a robotics infrastructure "is the only way to make sure we generate data of sufficient quality at the speed and scale required, and now everybody in the pharma industry is very excited about the idea of end-to-end automation." So says Martin-Immanuel Bittner, CEO of .
You may also be interested in...
The Swiss major is close to its first submission for ‘pipeline in a pill’ iptacopan but has conceded defeat with branaplam as a potential treatment for Huntington’s disease.
Europe does not have a pricing environment that rewards innovation which improves outcomes for patients, according to Vas Narasimhan, although Germany seems to be the best of a bad bunch.
The Swedish biotech is stepping up its business development plans ahead of a mid-stage readout in the summer for ACD440, its TRPV1 antagonist for neuropathic pain.